← back to search

Olaf Gefeller

Friedrich-Alexander-Universität Erlangen-Nürnberg · DE
Area of research
Dermatology · Oncology
Research interest
Research interests include Medicine, Seroprevalence, Population, Demography, Boosting (machine learning), and Computer science.
h-index
citations
639
works
11
NIH funding
primary concept
email

Recent publications

Clinical and immunological benefits of full primary COVID-19 vaccination in individuals with SARS-CoV-2 breakthrough infections: A prospective cohort study in non-hospitalized adults
Journal of Clinical Virology 2023cited by 7position: middledoi
Population-based study of the durability of humoral immunity after SARS-CoV-2 infection
Frontiers in Immunology 2023cited by 4position: middledoi
Time Trend in SARS-CoV-2 Seropositivity, Surveillance Detection- and Infection Fatality Ratio until Spring 2021 in the Tirschenreuth County—Results from a Population-Based Longitudinal Study in Germany
Viruses 2022cited by 11position: middledoi
Higher Infection Risk among Health Care Workers and Lower Risk among Smokers Persistent across SARS-CoV-2 Waves—Longitudinal Results from the Population-Based TiKoCo Seroprevalence Study
International Journal of Environmental Research and Public Health 2022cited by 6position: middledoi
Estimates and Determinants of SARS-Cov-2 Seroprevalence and Infection Fatality Ratio Using Latent Class Analysis: The Population-Based Tirschenreuth Study in the Hardest-Hit German County in Spring 2020
Viruses 2021cited by 37position: middledoi
Spectrum Bias and Individual Strengths of SARS-CoV-2 Serological Tests—A Population-Based Evaluation
Diagnostics 2021cited by 18position: middledoi
Estimates and determinants of SARS-CoV-2 seroprevalence and infection fatality ratio using latent class analysis: the population-based Tirschenreuth study in the hardest-hit German county in spring 2020
medRxiv 2021cited by 12position: middledoi
Randomised phase-III-trial of concurrent chemoradiation (CRT) for locally advanced head and neck cancer (stage III-IVB): Comparing dose reduced radiotherapy (63,6 Gy) with paclitaxel/cisplatinum to standard radiotherapy (70,6 Gy) with fluorouracil/cisplatinum.
Journal of Clinical Oncology 2017cited by 5position: middledoi
The Evolution of Boosting Algorithms
Methods of Information in Medicine 2014cited by 362position: middledoi
Prevalence and correlates of gout in a large cohort of patients with chronic kidney disease: the German Chronic Kidney Disease (GCKD) study
Nephrology Dialysis Transplantation 2014cited by 123position: middledoi
Extending Statistical Boosting
Methods of Information in Medicine 2014cited by 54position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Philipp Steininger · Friedrich-Alexander-Universität Erlangen-Nürnberg6 papers (2021–2023)Sebastian Einhauser · University of Regensburg6 papers (2021–2023)Iris M. Heid · University of Lausanne6 papers (2021–2023)Klaus Überla · Friedrich-Alexander-Universität Erlangen-Nürnberg6 papers (2021–2023)Felix Günther · University of Regensburg6 papers (2021–2023)Hans Helmut Niller · Institute of Medical Microbiology and Hygiene6 papers (2021–2023)Stephanie Beileke · Universitätsklinikum Erlangen6 papers (2021–2023)David Peterhoff · University of Regensburg6 papers (2021–2023)Ralf Wagner · University of Regensburg6 papers (2021–2023)Ralph Burkhardt · University Hospital Regensburg6 papers (2021–2023)Helmut Küchenhoff · Statistisches Bundesamt5 papers (2021–2023)Annette Pfahlberg · Friedrich-Alexander-Universität Erlangen-Nürnberg4 papers (2021–2022) · 3 papers (2021–2022)André Gessner · University Hospital Regensburg3 papers (2021–2022)Antje Knöll · Friedrich-Alexander-Universität Erlangen-Nürnberg3 papers (2021–2022)Simon Wiegrebe · University of Regensburg3 papers (2022–2023)Michael Kabesch · Université de Lorraine3 papers (2021–2022)Klaus Stark · University of Regensburg3 papers (2021–2022)Klaus Korn · Friedrich-Alexander-Universität Erlangen-Nürnberg3 papers (2021–2022)Melanie Berr · University of Regensburg3 papers (2021–2022)